COVID-19
Nephrology
Katherine Perry, MD, MSCR
UCLA
Thousand Oaks, California, United States
Juhi Kumar, MD, MPH
Associate Professor of Clinical Pediatrics
Weill Cornell Medicine, New Jersey, United States
Recognized only twenty years ago, FGF23 has been shown to function prominently in metabolic bone disease in pediatric renal patients. FGF23 originates in bone but the kidneys are among its chief effector sites. Its impact in chronic kidney disease (CKD), however, extends beyond canonic avenues of kidney-induced bone dysmetabolism to include cardiovascular ramifications. The era of FGF23 inhibition may, therefore, offer promise for better treatment and improved lives of pediatric patients with CKD. This session will provide an in depth overview of: the role of FGF23 in bon health in renal disease, FGF23 renal regulation of phosphate and calcitriol metabolism, the role & mechanisms of FGF23 & Klotho in hypertension/ cardiovascular disease, and review as a therapeutic target (including discussion of burosumab.)
Speaker: Dieter Haffner, MD – Hannover Medical School
Speaker: Jyothsna Gattineni, MD – UT Southwestern Medical Center
Speaker: Farzana Perwad, MD – UCSF Benioff Children's Hospital San Francisco
Speaker: Michelle Denburg, MD, MSCE – Childrens Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania